ProQR Therapeutics Stock Forecast, Price & News

ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

Is ProQR Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ProQR Therapeutics stock.
View analyst ratings for ProQR Therapeutics or view top-rated stocks.

How has ProQR Therapeutics' stock price been impacted by Coronavirus?

ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRQR stock has increased by 2.7% and is now trading at $7.19.
View which stocks have been most impacted by COVID-19.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for ProQR Therapeutics.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.01. ProQR Therapeutics had a negative net margin of 3,747.12% and a negative trailing twelve-month return on equity of 65.00%.
View ProQR Therapeutics' earnings history.

What price target have analysts set for PRQR?

6 brokerages have issued 12-month price targets for ProQR Therapeutics' shares. Their forecasts range from $17.00 to $44.00. On average, they anticipate ProQR Therapeutics' stock price to reach $26.14 in the next year. This suggests a possible upside of 263.6% from the stock's current price.
View analysts' price targets for ProQR Therapeutics or view top-rated stocks among Wall Street analysts.

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the following people:

• Daniel Anton de Boer, Chief Executive Officer
• Smital Shah, Chief Financial & Business Officer
• Aniz Girach, Chief Medical Officer
• Jennifer Pluim, Vice President-Medical Affairs
• Naveed K. Shams, Chief Scientific Officer

Who are some of ProQR Therapeutics' key competitors?

Some companies that are related to ProQR Therapeutics include Amarin (AMRN), NGM Biopharmaceuticals (NGM), Xenon Pharmaceuticals (XENE), Madrigal Pharmaceuticals (MDGL), Axsome Therapeutics (AXSM), COMPASS Pathways (CMPS), Endo International (ENDP), ALX Oncology (ALXO), MorphoSys (MOR), Nurix Therapeutics (NRIX), uniQure (QURE), Keros Therapeutics (KROS), Amneal Pharmaceuticals (AMRX), Organogenesis (ORGO) and PureTech Health (PRTC).
View all of PRQR's competitors.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (10.66%), Goldman Sachs Group Inc. (6.84%), Jennison Associates LLC (3.67%), Opaleye Management Inc. (2.84%), FIL Ltd (2.40%) and Rafferty Asset Management LLC (1.06%).

Which major investors are selling ProQR Therapeutics stock?

PRQR stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Assenagon Asset Management S.A., Morgan Stanley, Prosight Management LP, Rafferty Asset Management LLC, Two Sigma Investments LP, Cubist Systematic Strategies LLC, and Citigroup Inc..

Which major investors are buying ProQR Therapeutics stock?

PRQR stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Point72 Asset Management L.P., Millennium Management LLC, FIL Ltd, Altium Capital Management LP, Goldman Sachs Group Inc., GSA Capital Partners LLP, and Opaleye Management Inc..

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $7.19.

How much money does ProQR Therapeutics make?

ProQR Therapeutics has a market capitalization of $360.97 million and generates $10.80 million in revenue each year. The biopharmaceutical company earns $-53.19 million in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

ProQR Therapeutics employs 1,504 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is www.proqr.com.

Where are ProQR Therapeutics' headquarters?

ProQR Therapeutics is headquartered at Zernikedreef 9, Leiden P7, 2333 CK.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at [email protected].